LOGIN  |  REGISTER
Assertio
Assertio

89bio to Participate in Upcoming Investor Conferences

May 02, 2023 | Last Trade: US$9.14 0.24 2.70

SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management will participate in the following upcoming conferences in May:

  • BofA Securities 2023 Healthcare Conference
    Format: Presentation and one-on-one investor meetings
    Date: Tuesday, May 9, 2023
    Presentation Time: 5:35 p.m. ET
  • 2023 RBC Capital Markets Global Healthcare Conference
    Format: Fireside chat and one-on-one investor meetings
    Date: Wednesday, May 17, 2023
    Presentation Time: 8:30 a.m. ET

The webcasts of these presentation will be accessible in the investor section of 89bio’s website.

About 89bio 

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Ryan Martins 
Chief Financial Officer 
This email address is being protected from spambots. You need JavaScript enabled to view it.

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact: 
Sheryl Seapy
Real Chemistry
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB